COMPANY

Lohocla Research

HQ: Aurora, CO source · lohocla.com ↗ · Mountain

Clinical Phase 1

Also known as Lohocla Research Corporation · 40 sources

Keywords: chronic pain alcohol use disorder alcohol abuse Safety Evaluation of Escalating Doses

Location: Aurora, CO · source · Oct 14, 2026

Profile checked Oct 10, 2026

2Trials (company is sponsor)37NIH grants

Timeline

Jul 28, 2025 Grant Government grant — SBIR: $1.71M (annual award, as published), announced Jul 28, 2025. Agency: NIH/NIAAA. Source: government award database. source ↗
Feb 28, 2025 Trial start Phase 1: A Study to Test the Effects of Nezavist at Different Doses in Healthy Adults source ↗
Apr 21, 2024 Trial start Phase 1: A Study to Test the Effects of Kindolor at Different Doses in Healthy Adults source ↗

Funding

Last 2 years.

Jul 28, 2025 Government grant — SBIR: $1.71M (annual award, as published), announced Jul 28, 2025. Agency: NIH/NIAAA. Source: government award database. source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT06633562	A Study to Test the Effects of Nezavist at Different Doses in Healthy Adults	Phase 1	Terminated	Feb 28, 2025	Dec 22, 2025 (actual)
NCT06243835	A Study to Test the Effects of Kindolor at Different Doses in Healthy Adults	Phase 1	Terminated	Apr 21, 2024	Nov 22, 2024 (actual)

NIH awards 37

Annual award amounts. Total $30.9M.

Jun 24, 2024 NIH award 4R44AA024905-07 FY2024: $1,710,386 awarded for that fiscal year; activity R44 (SBIR); PI TABAKOFF, BORIS; recipient as written: LOHOCLA RESEARCH CORPORATION, Aurora, CO. Nezavist a Novel Molecule for Treatm source ↗
Mar 15, 2024 NIH award 3UH3DA047680-05S1 FY2024: $139,986 awarded for that fiscal year; activity UH3 (OTHER_NIH); PI TABAKOFF, BORIS; recipient as written: LOHOCLA RESEARCH CORPORATION, Aurora, CO. A novel therapeutic to ameliora source ↗
Jun 22, 2023 NIH award 5UH3DA047680-05 FY2023: $1,925,647 awarded for that fiscal year; activity UH3 (OTHER_NIH); PI TABAKOFF, BORIS; recipient as written: LOHOCLA RESEARCH CORPORATION, Aurora, CO. A novel therapeutic to ameliora source ↗
Aug 25, 2022 NIH award 2R44AA024905-06 FY2022: $1,710,532 awarded for that fiscal year; activity R44 (SBIR); PI TABAKOFF, BORIS; recipient as written: LOHOCLA RESEARCH CORPORATION, Aurora, CO. Nezavist a Novel Molecule for Treatm source ↗
Jun 24, 2022 NIH award 5UH3DA047680-04 FY2022: $3,283,785 awarded for that fiscal year; activity UH3 (OTHER_NIH); PI TABAKOFF, BORIS; recipient as written: LOHOCLA RESEARCH CORPORATION, Aurora, CO. A novel therapeutic to ameliora source ↗
Jul 12, 2021 NIH award 4UH3DA047680-03 FY2021: $3,973,837 awarded for that fiscal year; activity UH3 (OTHER_NIH); PI TABAKOFF, BORIS; recipient as written: LOHOCLA RESEARCH CORPORATION, Aurora, CO. A novel therapeutic to ameliora source ↗
Mar 5, 2021 NIH award 3U44AA024905-05S2 FY2021: $124,401 awarded for that fiscal year; activity U44 (SBIR); PI TABAKOFF, BORIS; recipient as written: LOHOCLA RESEARCH CORPORATION, Aurora, CO. Nezavist a Novel Molecule for Treatm source ↗
Aug 26, 2020 NIH award 3U44AA024905-05S1 FY2020: $212,652 awarded for that fiscal year; activity U44 (SBIR); PI TABAKOFF, BORIS; recipient as written: LOHOCLA RESEARCH CORPORATION, Aurora, CO. Nezavist a Novel Molecule for Treatm source ↗
Feb 24, 2020 NIH award 5UG3DA047680-02 FY2020: $3,270,473 awarded for that fiscal year; activity UG3 (OTHER_NIH); PI TABAKOFF, BORIS; recipient as written: LOHOCLA RESEARCH CORPORATION, Aurora, CO. A novel therapeutic to ameliora source ↗
Aug 23, 2019 NIH award 5U44AA024905-05 FY2019: $1,500,000 awarded for that fiscal year; activity U44 (SBIR); PI TABAKOFF, BORIS; recipient as written: LOHOCLA RESEARCH CORPORATION, Aurora, CO. Nezavist a Novel Molecule for Treatm source ↗
Mar 8, 2019 NIH award 1UG3DA047680-01 FY2019: $2,382,426 awarded for that fiscal year; activity UG3 (OTHER_NIH); PI TABAKOFF, BORIS; recipient as written: LOHOCLA RESEARCH CORPORATION, Aurora, CO. A novel therapeutic to ameliora source ↗
Feb 28, 2019 NIH award 3U44AA024905-04S1 FY2019: $918,712 awarded for that fiscal year; activity U44 (SBIR); PI TABAKOFF, BORIS; recipient as written: LOHOCLA RESEARCH CORPORATION, Aurora, CO. Nezavist a Novel Molecule for Treatm source ↗
Aug 21, 2018 NIH award 5U44AA024905-04 FY2018: $1,500,000 awarded for that fiscal year; activity U44 (SBIR); PI TABAKOFF, BORIS; recipient as written: LOHOCLA RESEARCH CORPORATION, Aurora, CO. Nezavist a Novel Molecule for Treatm source ↗
Sep 12, 2017 NIH award 4U44AA024905-03 FY2017: $1,500,000 awarded for that fiscal year; activity U44 (SBIR); PI TABAKOFF, BORIS; recipient as written: LOHOCLA RESEARCH CORPORATION, Aurora, CO. Nezavist a Novel Molecule for Treatm source ↗
Aug 12, 2016 NIH award 5U44AA024905-02 FY2016: $985,777 awarded for that fiscal year; activity U44 (SBIR); PI TABAKOFF, BORIS; recipient as written: LOHOCLA RESEARCH CORPORATION, Aurora, CO. Nezavist a Novel Molecule for Treatmen source ↗
Sep 23, 2015 NIH award 1U44AA024905-01 FY2015: $1,000,000 awarded for that fiscal year; activity U44 (SBIR); PI TABAKOFF, BORIS; recipient as written: LOHOCLA RESEARCH CORPORATION, Aurora, CO. Nezavist a Novel Molecule for Treatm source ↗
Jun 25, 2014 NIH award 5R43DA036211-02 FY2014: $158,240 awarded for that fiscal year; activity R43 (SBIR); PI TABAKOFF, BORIS; recipient as written: LOHOCLA RESEARCH CORPORATION, Aurora, CO. A Delta/Kappa OR Ligand: Taking Advant source ↗
Jul 15, 2013 NIH award 1R43DA036211-01 FY2013: $158,234 awarded for that fiscal year; activity R43 (SBIR); PI TABAKOFF, BORIS; recipient as written: LOHOCLA RESEARCH CORPORATION, Aurora, CO. A Delta/Kappa OR Ligand: Taking Advant source ↗
Sep 25, 2009 NIH award 3R44AA014531-05S1 FY2009: $74,999 awarded for that fiscal year; activity R44 (SBIR); PI SNELL, LAWRENCE DOUGLAS; recipient as written: LOHOCLA RESEARCH CORPORATION, Aurora, CO. Proteomic Markers of Alcohol source ↗
Sep 16, 2009 NIH award 3R44AA009930-05S1 FY2009: $146,873 awarded for that fiscal year; activity R44 (SBIR); PI SNELL, LAWRENCE DOUGLAS; recipient as written: LOHOCLA RESEARCH CORPORATION, Aurora, CO. Medications for the Treatmen source ↗
Sep 30, 2008 NIH award 1R43AA017374-01 FY2008: $240,065 awarded for that fiscal year; activity R43 (SBIR); PI SNELL, LAWRENCE DOUGLAS; recipient as written: LOHOCLA RESEARCH CORPORATION, Aurora, CO. Monoclonal antibody mediated b source ↗
Apr 11, 2008 NIH award 5R44AA009930-05 FY2008: $549,928 awarded for that fiscal year; activity R44 (SBIR); PI SNELL, LAWRENCE DOUGLAS; recipient as written: LOHOCLA RESEARCH CORPORATION, Aurora, CO. Medications for the Treatment source ↗
Sep 1, 2007 NIH award 5R44AA014531-05 FY2007: $474,865 awarded for that fiscal year; activity R44 (SBIR); PI SNELL, LAWRENCE DOUGLAS; recipient as written: LOHOCLA RESEARCH CORPORATION, AURORA, CO. Proteomic Markers of Alcohol A source ↗
May 14, 2007 NIH award 2R44AA009930-04 FY2007: $448,331 awarded for that fiscal year; activity R44 (SBIR); PI SNELL, LAWRENCE DOUGLAS; recipient as written: LOHOCLA RESEARCH CORPORATION, AURORA, CO. Medications for the Treatment source ↗
Aug 31, 2006 NIH award 5R44AA014531-04 FY2006: $475,542 awarded for that fiscal year; activity R44 (SBIR); PI SNELL, LAWRENCE DOUGLAS; recipient as written: LOHOCLA RESEARCH CORPORATION, AURORA, CO. Proteomic Markers of Alcohol A source ↗
Sep 1, 2005 NIH award 4R44AA014531-03 FY2005: $399,059 awarded for that fiscal year; activity R44 (SBIR); PI SNELL, LAWRENCE DOUGLAS; recipient as written: LOHOCLA RESEARCH CORPORATION, AURORA, CO. Proteomic Markers of Alcohol A source ↗
Aug 31, 2004 NIH award 5R44AA014531-02 FY2004: $198,114 awarded for that fiscal year; activity R44 (SBIR); PI SNELL, LAWRENCE DOUGLAS; recipient as written: LOHOCLA RESEARCH CORPORATION, AURORA, CO. Proteomic Markers of Alcohol A source ↗
Sep 30, 2003 NIH award 1R44AA014531-01 FY2003: $198,114 awarded for that fiscal year; activity R44 (SBIR); PI SNELL, LAWRENCE DOUGLAS; recipient as written: LOHOCLA RESEARCH CORPORATION, AURORA, CO. Proteomic Markers of Alcohol A source ↗
Sep 27, 2000 NIH award 1R43DA013059-01A1 FY2000: $156,875 awarded for that fiscal year; activity R43 (SBIR); PI SNELL, LAWRENCE DOUGLAS; recipient as written: LOHOCLA RESEARCH CORPORATION, AURORA, CO. PLATELET MAO AS A MARKER FOR source ↗
Jan 15, 1999 NIH award 3R44AA009930-03S1 FY1999: $99,948 awarded for that fiscal year; activity R44 (SBIR); PI SNELL, LAWRENCE DOUGLAS; recipient as written: LOHOCLA RESEARCH CORPORATION, AURORA, CO. MEDICATIONS FOR ALCOHOL WITHD source ↗